Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

After cancer: Study explores caring-healing modalities for survivors

2.

Study offers clearer picture of childhood brain tumor survival

3.

How AI will transform mental health support for patients with breast cancer

4.

Reversing the toxic relationship with high doses of chemotherapy in oncology.

5.

Rural residents continue to have higher odds of skin cancer, study finds


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot